OncoMatch/Clinical Trials/NCT05682755
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Is NCT05682755 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Chidamide for leukemia, myeloid, acute.
Treatment: Chidamide — The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia (AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • The efficacy and safety of chidamide maintenance therapy in reducing the recurrence rate and GVHD incidence in high-risk AML patients after allo-HSCT. Participants will take oral chidamide (Epidaza) until 180 days after allo-HSCT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Prior therapy
Must have received: stem cell transplant — allogeneic
Received allo-HSCT and achieved complete remission (CR)
Lab requirements
Blood counts
Hematopoietic reconstitution: neutrophil count ≥ 0.5×10^9/L for 3 consecutive days without G-CSF, platelet count ≥ 20×10^9/L for 7 consecutive days without platelet transfusion, Hb ≥ 80 g/L without red blood cell transfusion; and neutrophil count ≥ 1.5×10^9/L, platelet count ≥ 50×10^9/L within 45 days after transplantation
Kidney function
No serious functional damage to important organs; renal function exclusion
Liver function
No serious functional damage to important organs; decompensated hepatic insufficiency excluded
Cardiac function
No serious functional damage to important organs; myocardial infarction, chronic cardiac insufficiency, and history of prolonged QT syndrome excluded
No serious functional damage to important organs of the body; Serious basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated hepatic insufficiency, renal function, gastrointestinal insufficiency, etc.; History of prolonged QT syndrome
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify